Literature DB >> 35998972

Drug Development for Cystic Kidney Diseases.

Sorin Fedeles1, Ronald D Perrone2.   

Abstract

Entities:  

Keywords:  clinical trial; drug development; polycystic kidney disease; regulatory development

Year:  2022        PMID： 35998972      PMCID： PMC9528273          DOI： 10.2215/CJN.04910422

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN： 1555-9041            Impact factor:   10.614


× No keyword cloud information.
  5 in total

Review 1.  Clinical practice. Autosomal dominant polycystic kidney disease.

Authors:  Jared J Grantham
Journal:  N Engl J Med       Date:  2008-10-02       Impact factor: 91.245

2.  Perspectives on Drug Development in Autosomal Recessive Polycystic Kidney Disease.

Authors:  Max C Liebau; Erum A Hartung; Ronald D Perrone
Journal:  Clin J Am Soc Nephrol       Date:  2022-08-23       Impact factor: 10.614

3.  Perspectives on Drug Development in Early ADPKD.

Authors:  Djalila Mekahli; Hayley Womack; Neera K Dahl
Journal:  Clin J Am Soc Nephrol       Date:  2022-08-23       Impact factor: 10.614

4.  Current Challenges and Perspectives on Developing a Clinical Trial Design for ADPKD.

Authors:  Craig Ostroff; Ronald D Perrone; Frank S Czerwiec
Journal:  Clin J Am Soc Nephrol       Date:  2022-08-23       Impact factor: 10.614

5.  Systematic review on outcomes used in clinical research on autosomal recessive polycystic kidney disease-are patient-centered outcomes our blind spot?

Authors:  Charlotte Gimpel; Max Christoph Liebau; Franz Schaefer
Journal:  Pediatr Nephrol       Date:  2021-08-12       Impact factor: 3.714
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.